ASH 2022 | Investigating the efficacy of twice weekly ixazomib plus pom-dex in R/R multiple myeloma
Paul Richardson
• 11 Dec 2022
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, outlines findings of a Phase I/II study of twice weekly ixazomib plus pomalidomide and dexamethasone (pom-dex) in patients with relapsed/refractory (R/R) multiple myeloma (MM) (NCT04094961). Overall, results demonstrated that the regimen was well tolerated and elicited an encouraging and durable response rate in this higher-risk patient population. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
